13F Holdings
中文EN

ROIV Roivant Sciences Ltd.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1635088 · Fiscal year ends 03/31

Financial factors as of 2026-09-30 (2026Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY102.1%
TTM net income YoY7.9%
TTM EPS YoY-5.5%
Revenue 3-yr CAGR-16.2%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,358.1%
Net margin-838.2%
FCF margin-81.2%
EBITDA margin-1,352.0%

Returns

ROE-8.2%
ROA-6.9%
ROIC (approx.)-16.0%
Asset turnover0.01x

Leverage & solvency

Liabilities / assets7.6%
Debt / equity0.00x
Current ratio15.56x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.11x
Accruals ratio-6.1%
Payout ratio—
Capex / revenue-7.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252026-03-31FY20242025-03-31FY20232024-03-31FY20232023-03-31FY20222022-03-31
Income statement
Revenue$8.26M$29.05M$32.71M$31.53M$55.29M
R&D expense$681.81M$550.41M$439.91M$454.06M$483.04M
SG&A expense$610.47M$591.41M$416.13M$383.45M$775.03M
Operating income-$515.07M-$1.00B$4.50B-$906.76M-$1.35B
Interest expense——$34.78M$27.97M$7.04M
Pretax income-$264.58M-$681.59M$4.57B-$884.99M-$923.75M
Income tax$133.33M$48.17M$21.50M$4.08M$369,000
Net income-$299.77M-$171.98M$4.35B-$1.01B-$845.26M
EBITDA-$511.72M-$989.22M$4.52B-$887.91M-$1.35B
EPS (basic)-0.43-0.245.55-1.42-1.26
EPS (diluted)-0.54-0.245.23-1.42-1.26
Weighted avg. shares (diluted)693.86M725.40M831.05M712.79M669.75M
Balance sheet
Cash & equivalents$1.42B$2.72B$6.49B$1.69B$2.07B
Short-term investments$2.87B$2.17B$0——
Receivables——$3.99M$30.38M$3.88M
Inventory——$35.25M$2.76M$0
Current assets$5.17B$5.00B$6.73B$1.80B$2.15B
PP&E, net$11.99M$12.06M$15.32M$39.09M$25.91M
Intangibles——$137.84M$144.88M$0
Total assets$5.71B$5.44B$7.22B$2.39B$2.59B
Current liabilities$281.24M$149.41M$266.76M$272.45M$184.37M
Short-term debt——$12.00M$40.72M$0
Long-term debt——$430.59M$375.51M$210.03M
Total debt——$442.59M$416.24M$210.03M
Total liabilities$416.27M$249.74M$773.95M$782.02M$523.70M
Shareholders' equity$4.53B$4.69B$5.97B$1.16B$1.66B
Net debt——-$6.05B-$1.28B-$1.86B
Shares outstanding720.35M695.94M806.68M760.14M694.98M
Cash flow statement
Operating cash flow-$750.35M-$839.45M-$765.27M-$843.39M-$677.73M
Capital expenditure$8.21M$4.60M$1.38M$12.69M$17.44M
Free cash flow-$758.56M-$844.05M-$766.65M-$856.08M-$695.16M
Investing cash flow-$682.33M-$1.77B$5.20B-$44.27M$303.30M
Financing cash flow$134.24M-$1.22B$419.36M$499.46M$306.79M
Depreciation & amortization$3.35M$14.07M$22.04M$18.86M$5.93M
Stock-based compensation$346.17M$289.03M$199.63M$217.78M$564.96M
Share buybacks—$1.29B$0$0—

Free plan shows the latest 5 periods; Pro shows all 6 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.